To ensure accurate evaluation, the American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) implemented guidelines for HER2 evaluation in breast cancer in 2007 [12]. This evidence concerns the gene ERBB2 and breast cancer.